Search Within

Elisa De Stanchina

  1. "Gary Schwartz"
Formats
  1. Journal Article (6)
  2. Meeting Abstract (2)
Groups
  1. Department of Medicine (5)
  2. Solid Tumor Oncology Division (5)
  3. Sarcoma Service (3)
  4. GSK Faculty (2)
  5. Head and Neck Service (2)
  6. Molecular Pharmacology and Chemistry Program Faculty (1)

More Groups

People
  1. Gary Schwartz (8)
  2. Elgilda Musi (4)
  3. Grazia Ambrosini (3)
  4. Jayasree Nair (3)
  5. Alan Ho (2)
  6. Parag Patwardhan (2)

More People

Years
  1. 2014 (1)
  2. 2013 (2)
  3. 2012 (3)
  4. 2011 (1)
  5. 2009 (1)
Publications
  1. Clinical Cancer Research (3)
  2. Cancer Research (2)
  3. Molecular Cancer Therapeutics (2)
  4. PLoS ONE (1)
Publishers
  1. American Association for Cancer Research (7)
  2. Public Library of Science (1)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The phosphoinositide 3-kinase a selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells
    Journal Article

    Musi, E.; Ambrosini, G.; de Stanchina, E.; Schwartz, G. K.
    Molecular Cancer Therapeutics (2014)

    Fulltext@MSK | Save
  • MLN0128, an investigational selective TORC1/2 kinase inhibitor, demonstrates potent antitumor activity in preclinical models of soft tissue sarcoma
    Meeting Abstract

    Patwardhan, P.; Deraje Vasudeva, S.; Tap, W. D.; de Stanchina, E.; Schwartz, G. K.
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death
    Journal Article

    Ambrosini, G.; Musi, E.; Ho, A. L.; de Stanchina, E.; Schwartz, G. K.
    Molecular Cancer Therapeutics (2013)

    Fulltext@MSK | Save
  • PDGFR as a novel target for the treatment of malignant peripheral nerve sheath tumors
    Meeting Abstract

    Patwardhan, P.; Tap, W.; de Stanchina, E.; Schwartz, G. K.
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype
    Journal Article

    Ho, A. L.; Musi, E.; Ambrosini, G.; Nair, J. S.; Deraje Vasudeva, S.; de Stanchina, E.; Schwartz, G. K.
    PLoS ONE (2012)

    Fulltext@MSK | Save
  • The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: Preclinical investigations and results of a phase I dose-escalation clinical trial
    Journal Article

    Luke, J. J.; D'adamo, D. R.; Dickson, M. A.; Keohan, M. L.; Carvajal, R. D.; Maki, R. G.; de Stanchina, E.; Musi, E.; Singer, S.; Schwartz, G. K.
    Clinical Cancer Research (2012)

    Fulltext@MSK | Save
  • Imaging colon cancer response following treatment with AZD1152: A preclinical analysis of [18F]fluoro-2-deoxyglucose and 3′-deoxy-3′-[18F]fluorothymidine imaging
    Journal Article

    Moroz, M. A.; Kochetkov, T.; Cai, S.; Wu, J.; Shamis, M.; Nair, J.; de Stanchina, E.; Serganova, I.; Schwartz, G. K.; Banerjee, D.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • The topoisomerase i poison CPT-11 enhances the effect of the aurora B kinaseInhibitor AZD1152both in vitro and in Vivo
    Journal Article

    Nair, J. S.; de Stanchina, E.; Schwartz, G. K.
    Clinical Cancer Research (2009)

    Fulltext@MSK | Save